|
|
Article: ACE inhibitor/ARB combination does more harm than good.(Cardiovascular Medicine)(angiotensin-receptor blocker)(angiotensin-converting enzyme)
- Article from:
- Family Practice News
- Article date:
- May 1, 2008
CopyrightCOPYRIGHT 2008 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- Telmisartan is as effective as ramipril in reducing vascular events in high-risk patients, but combining the two drugs provides no incremental benefit and increases side effects.
That was the key message of ONTARGET (the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial), a 25,620-patient megatrial presented by Dr. Salim Yusuf at the annual meeting of the American College of Cardiology.
ONTARGET was designed to answer two clinically relevant questions: Is the angiotensin-receptor blocker (ARB) telmisartan an effective alternative to ramipril in the 20%-30% of patients who can't tolerate an angiotensin-converting ...